Pfizer, CVS, and Estee Lauder have reported their quarterly earnings with mixed results. Pfizer exceeded expectations with an adjusted EPS of $0.82, surpassing the estimated $0.54, and posted revenues of $14.9 billion against forecasts of $14.2 billion. The company also raised its FY adjusted EPS forecast from $2.05-$2.25 to $2.15-$2.35, and reported revenues from Paxlovid and Comirnaty at $2.04 billion and $345 million, respectively. CVS reported a lower than expected adjusted EPS of $1.31 compared to the estimated $1.69 and saw a revenue shortfall at $88.4 billion versus the expected $89.33 billion, also lowering its FY adjusted EPS forecast from at least $8.30 to at least $7. Estee Lauder beat expectations with an adjusted EPS of $0.97, against a forecast of $0.48, and slightly exceeded revenue expectations with $3.94 billion. Automatic Data Processing (ADP) also reported a positive outcome with an adjusted EPS of $2.88, beating the forecast of $2.79, and revenue of $5.3 billion, slightly above the expected $5.22 billion, with a forecast of FY revenue growth of 6% to 7% and new bookings growth of 4% to 7%.
Pfizer lifted its annual profit forecast on Wednesday, banking on cost cuts and better-than-expected demand for its COVID antiviral treatment and vaccine. https://t.co/5FTQS96hf3 https://t.co/5FTQS96hf3
$ADP | Automatic Data Processing Q3 24 Earnings: - Adj EPS: $2.88 (est $2.79) - Revenue: $5.30B (est $5.22B) - Sees FY Employer Services New Bookings +4% To +7% - Sees FY Rev +6% To +7%
Global Earnings | Pfizer sees FY adj EPS at $2.15 to $2.35 vs saw $2.05 to $2.25 @pfizer https://t.co/0wfre7QqtW
💰 ADP $ADP EPS. vs Forecast 2.88 / 2.79 🟢 Rev. vs Forecast 5.25B / 5.23B 🟢 Market Cap: 99.37B
$PFE PFIZER Q1 2024 EARNINGS REV. $14.49B, EST. $13.91B ADJ. EPS $0.82 VS EST. $0.51 PAXLOVID REV. $2.04B COMIRNATY REV. $345M, EST. $591.6M STILL SEES FY REV. $58.5B TO $61.5B SEES FY ADJ EPS $2.15 TO $2.35, EST. SAW $2.05 TO $2.25
$PFE PFIZER Q1 2024 EARNINGS REV. $14.49B, EST. $13.91B ADJ. EPS $0.82 VS $0.51 PAXLOVID REV. $2.04B COMIRNATY REV. $345M, EST. $591.6M STILL SEES FY REV. $58.5B TO $61.5B SEES FY ADJ EPS $2.15 TO $2.35, EST. SAW $2.05 TO $2.25
$PFE PFIZER Q1 2024 EARNINGS REV. $14.49B, EST. $13.91B ADJ. EPS $0.82 TO $0.51 PAXLOVID REV. $2.04B COMIRNATY REV. $345M, EST. $591.6M STILL SEES FY REV. $58.5B TO $61.5B SEES FY ADJ EPS $2.15 TO $2.35, EST. SAW $2.05 TO $2.25
$PFE | Pfizer Q1 24 Earnings: - Adj EPS: $0.82 (est $0.52) - Revenue: $14.9B (est $13.91B) - Sees FY Adj EPS $2.15 To $2.35, Saw $2.05 To $2.25 - Says No Share Repurchases Planned In 2024
$EL | Estee Lauder Q3 24 Earnings: - Adj EPS: $0.97 (est $0.48) - Revenue: $3.94B (est $3.91B) - Sees FY Adj EPS $2.14 To $2.24, Saw $2.08 To $2.23 - Sees FY EPS $1.96 To $2.09, Saw $2.04 To $2.20
$PFE Q1 Adj EPS $0.82 beats $0.54 Est. Sales $14.9B beat $14.2B Est. Revenue is ↓ 20% YoY though. Current financial guidance does not anticipate any share repurchases in FY'24.
$PFE PFIZER Q1 2024 EARNINGS REV. $14.49B, EST. $13.91B ADJ. EPS $0.82 TO $0.51 STILL SEES FY REV. $58.5B TO $61.5B SEES FY ADJ EPS $2.15 TO $2.35, EST. SAW $2.05 TO $2.25
$PFE PFIZER Q1 2024 EARNINGS
$PFE | Pfizer Q1 Earnings: - Adj EPS $0.82 (Est. $0.54) 🟢 - Sales $14.90B (Est. $14.20B) 🟢
💰 Pfizer $PFE EPS. vs Forecast 0.82 / 0.53 🟢 Rev. vs Forecast 14.9B / 14.04B 🟢 Market Cap: 145.07B
$CVS | CVS Q1 24 Earnings: - Adj EPS: $1.31 (est $1.69) - Revenue: $88.4B (est $89.33B) - Sees FY Adj EPS At Least $7, Saw At Least $8.30 (est $8.29) - Adj Operating Income $2.96B (est $3.58B) - Net Rev $88.44B (est $89.33B) - Comp Sales +5.3% (est +3.95%)